INTERIM REPORT 1 JULY – 30 SEPTEMBER 2017
Third quarter 2017, compared to 2016, Group» 50% growth in orders for Episealer® knee implants during the quarter with 42 (28) approved orders. Invoicing taking place at delivery during both Q3 and Q4 2017» Group net sales increased by 1% to SEK 520,284 (516,641)» Other operating income amounted to SEK 97,716 (–)» Loss before tax amounted to SEK –13,518,593 (–15,042,517)» Earnings per share (weighted average) amounted to SEK –0.45 (–0.79) Significant events during the third quarter» 100 patient multi-center study of the Episealer® knee implant fully recruited» Episurf